샘플 요청 목록

 카트 문의
시장보고서
상품코드
1513950

세계의 중간엽 줄기세포(MSC) 시장

Mesenchymal Stem Cells (MSC)
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 202 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

중간엽 줄기세포(MSC) 세계 시장은 2030년까지 106억 달러에 달할 전망

2023년 47억 달러로 추정되는 중간엽 줄기세포(MSC) 세계 시장은 분석 기간 2023-2030년에 12.2%의 연평균 복합 성장률(CAGR)로 성장하고 2030년에는 106억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 골수 유래 MSC는 CAGR 13.1%로 성장을 지속하고, 분석 기간 종료 시에는 34억 달러에 달할 것으로 예상됩니다. 지방 조직 유래 MSC 부문의 성장률은 분석 기간 동안 CAGR 14.7%로 추정됩니다.

미국 시장은 13억 달러로 추정, 중국은 CAGR 11.4%로 성장 예측

미국의 중간엽 줄기세포(MSC) 시장은 2023년 13억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 16억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 11.4%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 10.6%와 10.1%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 8.3%로 성장할 것으로 예측됩니다.

세계의 중간엽 줄기세포(MSC) 시장- 주요 동향과 촉진요인 정리

중간엽 줄기세포(MSCs)는 골수, 지방조직, 제대조직 등 다양한 조직에 존재하는 성체 줄기세포의 일종으로, 재생의료나 다양한 병태의 치료에의 응용이 기대되고 있습니다. 이러한 세포는 자기 복제 능력과 뼈, 연골, 근육, 신경 세포 등 다양한 세포 계보로 분화하는 능력으로 특이합니다. 특히 면역 거부 반응을 피할 수 있기 때문에 그 가능성은 매우 매력적이며 임상 응용에 대한 적성을 높이는 중요한 요소가 되고 있습니다. MSC의 분화 능력은 세포공급원과 배양 조건 등 다양한 요인에 의해 영향을 받습니다. 이 과정은 활성화, 증식, 성숙을 제어하는 복잡한 유전적 및 후성적 메커니즘에 지배됩니다.

MSC는 또한 면역반응을 억제하고 조직 복구를 촉진하는데 중요한 면역조절 특성을 나타내며, 자가면역 질환, 척수 손상, 심혈관 질환의 치료에 귀중한 존재가 되었습니다. MSC는 혈관 신생과 조직 재생을 촉진하고 다양한 병리의 관리에서 그 중요성을 강조합니다. MSCs는 다양한 조직에서 공급되며, 각각은 분리 및 성장 측면에서 독특한 이점과 도전을 제공합니다. 그러나, 그 임상 응용은 세포의 불균일성, 변동, 품질 관리의 필요성 등의 과제에 의해 방해되고 있습니다. MSC의 치료 가능성을 효과적으로 이용하기 위해서는 표준화된 방법론을 개발하고 엄격한 안전성 평가를 수행하는 것이 필수적입니다.

암 영역에서 MSC는 이중 역할을 담당합니다. MSC는 혈관신생을 촉진하고, 면역 회피를 촉진하고, 종양을 지지하는 미세환경을 형성함으로써 종양의 증식에 기여하는 것으로 나타났습니다. 반대로 MSC는 항종양성을 나타내며 사이토카인이나 다른 세포독성 요소를 배치하여 암세포를 표적으로 합니다. 이 이중의 성질로부터, 암 치료에 있어서의 MSC의 이용을 최적화하기 위해서는 MSC의 거동에 관한 미묘한 이해가 필요합니다. 연구자들은 MSC를 항암제의 딜리버리 차량으로 활용하여 종양에 직접 치료제를 운반할 수 있는 '트로이 목마'로 변신시키는 혁신적인 전략을 모색하고 있습니다. 세포를 비계로 하여 치료제의 방출을 제어할 수 있는 생체재료와 MSC의 조합은 현재 치료의 한계를 극복하고 암 치료의 효능을 높이는 유망한 길을 보여줍니다.

조사 대상 기업 예(총 56건)

  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen US Inc.
  • Genlantis Inc.
  • Lonza Group
  • Mesoblast Limited
  • MilliporeSigma
  • Neuromics
  • Orthofix International NV
  • PromoCell GmbH
  • R&D Systems Inc.
  • ScienCell Research Laboratories
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Thermo Fischer Scientific Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 세계 기타 지역

제4장 경쟁

JHS 24.07.24

Global Mesenchymal Stem Cells (MSC) Market to Reach US$10.6 Billion by 2030

The global market for Mesenchymal Stem Cells (MSC) estimated at US$4.7 Billion in the year 2023, is expected to reach US$10.6 Billion by 2030, growing at a CAGR of 12.2% over the analysis period 2023-2030. Bone Marrow-sourced MSC, one of the segments analyzed in the report, is expected to record a 13.1% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Adipose Tissues-sourced MSC segment is estimated at 14.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 11.4% CAGR

The Mesenchymal Stem Cells (MSC) market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.6% and 10.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Mesenchymal Stem Cells (MSC) Market - Key Trends and Drivers Summarized

Mesenchymal stem cells (MSCs), a type of adult stem cell found in various tissues such as bone marrow, adipose tissue, and umbilical cord tissue, hold significant promise for regenerative medicine and therapeutic applications across a spectrum of medical conditions. These cells are prized for their ability to self-renew and differentiate into a variety of cell lineages, including bone, cartilage, muscle, and nerve cells. Their potential is particularly compelling because they can evade immune rejection, a critical factor that enhances their suitability for clinical applications. The ability of MSCs to differentiate is influenced by various factors, including the source of the cells and the conditions under which they are cultured. This process is governed by complex genetic and epigenetic mechanisms that regulate their activation, proliferation, and maturation.

MSCs also exhibit immunomodulatory properties that are crucial for suppressing immune responses and fostering tissue repair, making them valuable in the treatment of autoimmune diseases, spinal cord injuries, and cardiovascular diseases. They promote angiogenesis and tissue regeneration, underscoring their importance in managing diverse medical conditions. MSCs are sourced from a range of tissues, each offering unique advantages and challenges in terms of isolation and expansion. However, their clinical application is hindered by challenges such as cellular heterogeneity, variability, and the need for quality control. To harness the therapeutic potential of MSCs effectively, it is essential to develop standardized methodologies and conduct rigorous safety evaluations.

In the oncological arena, MSCs present a dual role. They have been shown to contribute to tumor growth by promoting angiogenesis, immune evasion, and creating a tumor-supportive microenvironment. Conversely, they exhibit anti-tumor properties, deploying cytokines and other cytotoxic elements to target cancer cells. This dual nature necessitates a nuanced understanding of MSC behavior to optimize their therapeutic use in cancer treatment. Researchers are exploring innovative strategies to leverage MSCs as delivery vehicles for anti-cancer agents, transforming them into 'Trojan horses' that can carry therapeutic payloads directly to tumors. The combination of MSCs with biomaterials, which can scaffold the cells and control the release of therapeutic agents, presents a promising avenue to overcome current therapeutic limitations and enhance the efficacy of cancer treatments.

Select Competitors (Total 56 Featured) -

  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen US Inc.
  • Genlantis Inc.
  • Lonza Group
  • Mesoblast Limited
  • MilliporeSigma
  • Neuromics
  • Orthofix International N.V.
  • PromoCell GmbH
  • R&D Systems Inc.
  • ScienCell Research Laboratories
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Thermo Fischer Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Mesenchymal Stem Cells (MSC) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Regenerative Medicine Advances Propel Demand for Mesenchymal Stem Cells
    • Aging Global Population Drives Growth in MSC-Based Therapies
    • Technological Breakthroughs in Stem Cell Proliferation and Preservation Enhance MSC Therapeutic Viability
    • Expanding Clinical Trials Spotlight Efficacy of MSCs in Diverse Diseases
    • Rising Prevalence of Autoimmune Diseases Accelerates MSC Research and Applications
    • Growing Investment in Biotechnology Strengthens the Business Case for MSC Development
    • Collaboration between Academia and Industry Spurs Innovations in MSC Research
    • Enhanced Delivery Techniques Improve MSC Therapeutic Outcomes
    • Personalized Medicine Trends Catalyze Targeted MSC Therapy Developments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mesenchymal Stem Cells (MSC) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Adipose Tissues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Fetal Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Sources of MSC Isolation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Disease Modelling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Drug Development & Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Toxicology Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Italy 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: UK 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 110: Rest of World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of World Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 113: Rest of World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of World Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제